MARKET

ESPR

ESPR

Esperion Therape
NASDAQ
3.150
0.000
0.00%
After Hours: 3.140 -0.01 -0.31% 17:00 06/25 EDT
OPEN
3.150
PREV CLOSE
3.150
HIGH
3.160
LOW
3.150
VOLUME
8.82M
TURNOVER
--
52 WEEK HIGH
4.175
52 WEEK LOW
0.9490
MARKET CAP
811.73M
P/E (TTM)
-52.6756
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ESPR last week (0615-0619)?
Weekly Report · 3d ago
Top Esperion Executives Quietly Unload a Wave of Shares
TipRanks · 06/19 02:06
Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR
Barchart · 06/17 14:25
Esperion clears key U.S. antitrust hurdle for merger
TipRanks · 06/16 21:03
Esperion Therapeutics announces special shareholder meeting on merger agreement
PUBT · 06/16 20:01
Weekly Report: what happened at ESPR last week (0608-0612)?
Weekly Report · 06/15 09:19
Esperion Gains German Approval for ArchiMed Acquisition Deal
TipRanks · 06/09 21:07
Esperion Therapeutics announces shareholder meeting on merger agreement
PUBT · 06/09 20:02
More
About ESPR
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering cardiometabolic and rare/orphan disease therapies. It markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels who are at risk of cardiovascular disease and nasal spray, loop diuretic for the treatment of edema associated with congestive heart failure, and hepatic and renal disease. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. NEXLETOL is a first-in-class ACLY inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating LDL receptors. NEXLIZET contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and cholesterol absorption in the intestine. Its Enbumyst is the FDA-approved nasal spray loop diuretic.

Webull offers Esperion Therapeutics Inc stock information, including NASDAQ: ESPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ESPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ESPR stock methods without spending real money on the virtual paper trading platform.